PFM Health Sciences’s Soleno Therapeutics SLNO Stock Holding History

PFM Health Sciences’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-248,180	Closed	-$8.31M	–	109
2026 Q1	$8.31M	Buy	248,180 +287	+0.1%	+$11.3K	0.76%	45
2025 Q4	$11.5M	Buy	247,893 +4,492	+2%	+$246K	1.14%	32
2025 Q3	$16.5M	Sell	243,401 -163,801	-40%	-$12.1M	1.27%	25
2025 Q2	$34.1M	Sell	407,202 -188,004	-32%	-$14.1M	2.9%	8
2025 Q1	$42.5M	Buy	595,206 +287,703	+94%	+$14M	3.09%	10
2024 Q4	$13.8M	Buy	+307,503	New	+$15.9M	0.86%	34

PFM Health Sciences's SLNO Position: Q2 2026 in Review

PFM Health Sciences sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 248,180 shares — an estimated $8.31M sold.

PFM Health Sciences first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $42.5M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

PFM Health Sciences reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
PFM Health Sciences sold 248,180 Soleno Therapeutics shares in Q2 2026, an estimated $8.31M.
PFM Health Sciences first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
PFM Health Sciences's Soleno Therapeutics position peaked at $42.5M in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.